Corporate VCs Play a Larger Role in VC Scene to Start ’12
Corporate venture capitalists are again placing more bets with startups, particularly software and cleantech companies, according to a new study.
Corporate investors during the first half of the year participated in 16.3% of venture deals, according to the report from PricewaterhouseCoopers, the National Venture Capital Association and Thomson Reuters, publisher of this blog. This is an increase from 14.7% in 2011 and 12.9% in 2010.
The increase returns corporate participation in venture to levels common in the middle of the last decade. In 2008, a peak year, 20% of venture deals had corporate VCs in their syndicates.
Dollars have lagged a bit behind deals. Corporate VCs so far this year have invested $1.03 billion in 280 deals, the study found. This compares with $2.3 billion for all of last year. Still, this year’s six-month dollar total represents 7.8% of venture dollars invested compared with 7.7% last year.
Over the past 11 years, 7.8% participation is the average. Still, stateside startups shouldn’t get too excited–Intel’s venture arm is looking to take on deals overseas, one of its senior leaders recently stated .
So far this year, corporate deal size is $3.67 million, down from $4.01 million last year. Over the past six quarters, 27.1% of dollars went to software companies and 18.8% to cleantech startups.
Find a link to the study here.
Photo courtesy of Shutterstock.






Jay Caplan said on July 31, 2012
In January, Bruce Booth of Atlas Ventures wrote about the large and increasing role of corporate VC’s in life science deals: http://lifescivc.com/2012/01/corporate-pharma-vcs-preferred-partners-big-funds/